About Bienta

Bienta is a trademark for preclinical biology services of Enamine, the world’s largest supplier of drug-like molecules for drug discovery research. Bienta is operating as a Contract Research Organisation (CRO) providing biomolecular screening (HTS) services as well as comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) testing as well as pharmacokinetics (PK), toxicity and efficacy studies in animals.

High Throughput Screening & ADME Services

HTS Lab at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities as well as the capacity to run both biochemical and cell-based assays in 384-well plate format. Bioanalytical Lab is established to provide all common in vitro ADMET tests as well as analytical support of pharmacokinetics and animal toxicity services.

Discover your molecules with us

News & Events

Bienta scientists took IACUC courses

Congratulations to Vitalii Semirenko and Olga Vadzyuk who successfully completed CITIProgram courses on Post-Approval Monitoring and IACUC Chair in April 2020. These valuable courses help to manage effective work of Bienta Animal Care and Use Committee (BACUC) and magnify efforts on humane using of laboratory animals in Ukraine....

Conference Posters

In September, several Bienta scientisits will be attending international meetings: 4th INTERNATIONAL MASS SPECTROMETRY SCHOOL (IMSS), Barcelona, Spain, September 15-20, 2019: Maria Kliachyna will be presenting a poster: “Application of Tandem Mass Spectrometry to Study Drug Metabolism and Metabolism-Mediated Drug Interaction”. BASEL LIFE 2019, Basel, Switzerland, September 9-12, 2019: Anastasiia Gryniukova will be presenting a poster: “Discovery of MYST1 small-molecule inhibitors as...

2nd International Helmholtz Drug Discovery Conference, Apr 26-27, 2018, at Helmholtz Zentrum München

We are proud to announce that Enamine/Bienta is a Silver Sponsor of the 2nd International Helmholtz Drug Discovery Conference, Apr 26-27, 2018, at Helmholtz Zentrum München. Our poster “Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors” can be accessed here....

Read More